Infants with congenital heart disease have more frequent infections and exposures to antibiotics than healthy infants. It is unknown how congenital heart disease affects the development of bacterial colonization of the intestines. It is also unknown whether probiotics will change the bacteria in the intestine of infants with heart disease to become more like those of healthy infants without heart disease. This pilot trial is designed to address these two questions.
Infants with cyanotic congenital heart disease will be randomly assigned to receive either a placebo or probiotic Bifidobacterium infantis. Comparisons will be made between the infants receiving the placebo and healthy infants without heart disease and between the infants receiving the placebo and those receiving the probiotic.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
QUADRUPLE
Enrollment
12
1 billion organisms twice daily either through a feeding tube or by mouth for 4 months
A dilute preparation of pregestimil formula (similar in appearance to the probiotic product)
UC Davis Children's Hospital
Sacramento, California, United States
Fecal microbiota
Time frame: Weekly for 4 weeks then monthly
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.